Imunon, Inc. Announces Special Stockholder Meeting for Reverse Stock Split

Ticker: IMNN · Form: 8-K · Filed: Jun 13, 2024 · CIK: 749647

Imunon, INC. 8-K Filing Summary
FieldDetail
CompanyImunon, INC. (IMNN)
Form Type8-K
Filed DateJun 13, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: reverse-stock-split, shareholder-meeting

TL;DR

Imunon is doing a 1-for-100 reverse split on July 15th to boost its stock price.

AI Summary

On June 13, 2024, Imunon, Inc. filed an 8-K report detailing a special meeting of stockholders scheduled for July 15, 2024. The primary purpose of this meeting is to vote on a proposed reverse stock split of the company's common stock, with a ratio of 1-for-100. This action is intended to increase the per-share market price of the company's common stock.

Why It Matters

This reverse stock split is a significant corporate action that could impact the stock's trading price and potentially its eligibility for listing on major exchanges.

Risk Assessment

Risk Level: medium — Reverse stock splits are often undertaken by companies facing delisting or low stock prices, which can indicate underlying business challenges.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of the special meeting of stockholders for Imunon, Inc. on July 15, 2024?

The primary purpose is to vote on a proposed reverse stock split of the company's common stock at a ratio of 1-for-100.

What is the proposed ratio for the reverse stock split?

The proposed ratio is 1-for-100.

When is the special meeting of stockholders scheduled to take place?

The special meeting is scheduled for July 15, 2024.

What is the stated goal of the reverse stock split?

The stated goal is to increase the per-share market price of Imunon, Inc.'s common stock.

What is the filing date of this 8-K report?

The filing date of this 8-K report is June 13, 2024.

Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-13 09:00:12

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Dated: June 13, 2024 By: /s/ David Gaiero David Gaiero Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing